Education
About Us
Working with TipRanks
Follow Us
Winton Matthew Insider Profile
4 Followers
Winton Matthew, COO at Inozyme Pharma, holds 15.00K shares in CervoMed (Ticker: CRVO), holds 0.00 shares in Inozyme Pharma (Ticker: INZY). Most recently, Winton Matthew Bought ― shares of CervoMed on Nov 19, 2025 for an estimated value of $41.43K.
Winton Matthew Inozyme Pharma (INZY)COO
Inozyme Pharma (INZY)
COO
Not Ranked
Winton Matthew has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Chief Commercial and Business
Roles that Winton Matthew holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Winton Matthew
Winton Matthew's Trading History
Inozyme Pharma
Jul 03, 2025
―
Uninformative Sell
86.97K
$0.00
CervoMed
Nov 19, 2025
Chief Commercial and Business
Informative Buy
41.43K
$149.10K
List of latest transactions for each holding click on a transaction to see Winton Matthew's performance on stock
You May Also Like
Winton Matthew insider profile FAQ
What is the percentage of profitable transactions made by Winton Matthew?
The percentage of profitable transactions made by Winton Matthew is ―.
What is the average return per transaction made by Winton Matthew?
The average return per transaction made by Winton Matthew is ―.
What stocks does Winton Matthew hold?
Winton Matthew holds: INZY, CRVO stocks.
What was Winton Matthew’s latest transaction?
Winton Matthew latest transaction was an Informative Buy of $41.43K.
What was Winton Matthew's most profitable transaction?
Winton Matthew’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Winton Matthew's role in Inozyme Pharma?
Winton Matthew's role in Inozyme Pharma is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.